Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...

The Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA) issued draft recommendations for sponsors looking to develop drugs to treat nonalcoholic steatohepatitis ...

Researchers evaluated pegylated interferon-alpha (Peg-IFN-α) therapy in patients with Child-Pugh class A cirrhosis and found no higher risk of liver decompensation or severe adverse events compared to ...

—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at ...

Efruxifermin showed significant efficacy in reversing cirrhosis in MASH patients, with 39% achieving reversal compared to 15% on placebo. The study's results suggest efruxifermin's potential as a ...

The aim of the SPECCIAL (Surgical Procedures Eliminate Compensated Cirrhosis In Advancing Long-term) study was to examine the long-term outcomes of bariatric surgery on the risk of developing major ...

Please provide your email address to receive an email when new articles are posted on . Metabolic surgery reduced major adverse liver outcomes in patients with MASH with compensated cirrhosis by 72%.

--In the trial, aldafermin treatment up to one year was generally well tolerated with no treatment-related serious adverse events-- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NGM ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — Bulevirtide monotherapy was safe and ...

A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of developing serious liver ...